Overview
Location
United States, Massachusetts, Boston
Employees
11-50
Total raised
$75.5M
Founded date
2010
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Sep 3, 2013 | Series B round | $20M | |
| Feb 28, 2011 | Series A round | $10M |
Mentions in press and media 13
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 16, 2017 | Term Sheet — Thursday, November 16 | THE HOTTEST CEO IN SILICON VALLEY Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop Huang, 54, is the cofounder and CEO of semiconductor and software company Nvidia. The company’s “gra... |
| Oct 23, 2017 | Google, Gates-backed Arsanis eyes $58M IPO | Arsanis is gunning for a $58 million IPO as it seeks a new cash load for its work on using monoclonal antibodies (mAbs) for infectious diseases. This comes just five months after Arsanis raised a solid chunk of cash, $45.5 million, in its l... |
| Apr 27, 2017 | Term Sheet — Thursday, April 27 | PETER PAN NEVER HAD TO GROW UP The following article is from Fortune’s latest issue. Paid Content What you need to know about growing cyberattacks From ExtraHop They’re so exuberant, one VC even declared on CNBC that this year “could be one... |
| Apr 27, 2017 | Arsanis Completes $45.5 Million Series D Financing | Company set to advance pipeline of monoclonal antibodies for serious infectious diseases, including lead Phase 2 program ASN100 for the prevention of Staphylococcus aureus pneumonia in high-risk ICU patients |
| Apr 26, 2017 | Gates, Google-backed Arsanis ties off $45.5M Series D for mAb infection trials | Infectious disease specialist Arsanis has raised a solid chunk of cash, $45.5 million, in its latest funding round as it picks up the Bill & Melinda Gates Foundation and Alphabet's Google Ventures (GV) as backers. Arsanis designs a... |
| Apr 26, 2017 | Arsanis Closed $45.5M Series D Funding | Arsanis, Inc., a Waltham, Massachusetts-based clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, closed a $45.5m Series D fi... |
| Apr 26, 2017 | Gates, Google-backed Arsanis ties off $45.5M Series D for mAb infection trials W h i t e p a p e r Weighing the Costs: | Infectious disease specialist Arsanis has raised a solid chunk of cash, $45.5 million, in its latest funding round as it picks up the Bill & Melinda Gates Foundation and Alphabet's Google Ventures (GV) as backers. Sponsored by Agil... |
| Apr 26, 2017 | Arsanis Completes $45.5M Series D Financing | WALTHAM, MA, Arsanis announced the closing of a $45.5 million Series D financing led by the Bill & Melinda Gates Foundation. >> Click here for more funding data on Arsanis >> To export Arsanis funding data to PDF and Exc... |
| Apr 26, 2017 | Arsanis Completes $45.5 Million Series D Financing |
Show more
Reviews 0
FAQ about Arsanis, Inc.
When was Arsanis, Inc. founded?
Arsanis, Inc. was founded in 2010.
How much funding has Arsanis, Inc. raised?
Arsanis, Inc. has raised $75.5M in total across 3 funding rounds.
What funding rounds has Arsanis, Inc. raised?
Parsers VC lists 3 funding rounds of Arsanis, Inc., among them a Series B round of $20M on Sep 3, 2013 and a Series A round of $10M on Feb 28, 2011.
What has the press written about Arsanis, Inc.?
Parsers VC has collected 13 articles mentioning Arsanis, Inc., among them “Term Sheet — Thursday, November 16” (Nov 16, 2017) and “Google, Gates-backed Arsanis eyes $58M IPO” (Oct 23, 2017).
Is Arsanis, Inc. still active?
Arsanis, Inc. is probably closed: its latest activity on Parsers VC dates from Oct 3, 2023.